Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

NCT: NCT07568015 · RECRUITING

NCT IDNCT07568015
StatusRECRUITING
Start Date2026-07-27
Completion2029-11-01
SponsorBrixton Biosciences, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑